Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
Amitriptyline hydrochloride (HB1794)
Description:Serotonin/norepinephrine reuptake inhibitor (SNRI)
Purity:>98%
Anisomycin (HB2239)
Description:Protein synthesis inhibitor. Potent JNK / p38 MAPK activator.
Purity:>98%
DL-AP4 Sodium salt (HB0250)
Description:Water soluble form of DL-AP4, non-selective glutamate antagonist
Purity:>99%
D-AP5 (HB0225)
Description:Selective, competitive NMDA receptor antagonist. Inhibits NMDAR-synaptic plasticity.
Purity:>99%